Google founder Hassabis’ company plans to launch clinical trials of AI-developed drugs by the end of the year

Recently, Demis Hassabis, one of the founders of Google, revealed in an interview that the company he founded, Isomorphic Labs, plans to start a clinical trial of a drug developed by artificial intelligence (AI) before the end of the year. . The news has attracted widespread attention, particularly for potential applications in areas such as oncology, cardiovascular disease, and neurodegenerative diseases.

Isomorphic Labs was founded in 2021 to accelerate drug discovery and development using advanced artificial intelligence technology. Hassabis said that although the process of drug development is usually long and complex, with the support of artificial intelligence, potential compounds can be screened in a short time, greatly shortening the development cycle. He pointed out that the company is currently conducting a series of experiments to ensure that the drugs developed are not only effective but also safe.

Hassabis is confident in the application of artificial intelligence in life sciences. He believes that AI can extract important information from massive biomedical data, thereby helping scientists understand disease mechanisms and find treatment options faster. He mentioned that the team at Isomorphic Labs is committed to studying major diseases such as tumors, heart disease, and Alzheimer's disease, with a view to changing the status quo through the development of new drugs.

Currently, Isomorphic Labs has established cooperative relationships with a number of pharmaceutical companies and research institutions to jointly advance the drug research and development process. Hassabis emphasized that this cooperation will help speed up the clinical trials and marketing process of drugs. He also said that despite facing many challenges and uncertainties, the team remains enthusiastic and believes that future results will bring good news to patients around the world.

When talking about his future vision, Hassabis said he hopes to truly change people's understanding of and treatment of diseases through this AI-driven drug research and development program. He emphasized that the combination of science and technology will promote the development of medicine and provide patients with better treatment options.